Turnstone Biologics (TSBX) Stock Price, News & Analysis

Company Overview

Turnstone Biologics, Inc. (NASDAQ: TSBX) is a clinical-stage biopharmaceutical company pioneering next-generation viral immunotherapies for the treatment of solid tumors. The company’s proprietary platform harnesses engineered oncolytic viruses to selectively infect and lyse cancer cells while simultaneously delivering genetic payloads that stimulate a potent anti-tumor immune response. By combining direct tumor debulking with immune modulation, Turnstone aims to address cancers that have demonstrated resistance to conventional therapies.

Turnstone’s pipeline includes multiple clinical-stage candidates targeting a range of solid tumor indications. Lead programs leverage distinct viral backbones engineered to carry immunostimulatory cytokines, bispecific T-cell engagers or immune checkpoint modulators. These investigational therapies are currently being evaluated in Phase 1/2 trials for hepatocellular carcinoma, pancreatic cancer and virus-associated malignancies such as HPV+ head and neck squamous cell carcinoma. Early-stage assets in preclinical development explore next-generation constructs designed to improve tumor targeting and expand the reach of the platform.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Turnstone Biologics completed its merger with a special purpose acquisition company in early 2021 and began trading on the Nasdaq under the ticker symbol TSBX. The company is led by an experienced management team with deep expertise in oncology drug development, virology and translational medicine. Turnstone collaborates with leading academic institutions and leverages global clinical trial networks to advance its mission of delivering durable, virus-based immunotherapies to patients with high-unmet-need tumors.

Key Stats

• Today's Range: $0.36 to $0.36
• 50-Day Range: $0.35 to $0.37
• 52-Week Range: $0.29 to $2.42
• Volume: N/A
• Average Volume: 142,319 shs
• Market Capitalization: $8.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.45
• Consensus Rating: Reduce

Turnstone Biologics Stock Analysis - MarketRank™

Turnstone Biologics scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Turnstone Biologics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Turnstone Biologics has a consensus price target of $0.45, representing about 26.8% upside from its current price of $0.36.

Amount of Analyst Coverage

Turnstone Biologics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Turnstone Biologics are expected to grow in the coming year, from ($3.32) to ($0.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Turnstone Biologics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Turnstone Biologics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Turnstone Biologics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.50% of the float of Turnstone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Turnstone Biologics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Turnstone Biologics has recently decreased by 8.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Turnstone Biologics does not currently pay a dividend.

Dividend Growth

Turnstone Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.50% of the float of Turnstone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Turnstone Biologics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Turnstone Biologics has recently decreased by 8.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Turnstone Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.10% of the stock of Turnstone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSBX Stock Analysis - Frequently Asked Questions

How were Turnstone Biologics' earnings last quarter?

Turnstone Biologics Corp. (NASDAQ:TSBX) announced its earnings results on Friday, August, 8th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.08.

When did Turnstone Biologics IPO?

Turnstone Biologics (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at a price of $12.00 per share.

Who are Turnstone Biologics' major shareholders?

Turnstone Biologics' top institutional shareholders include Deltec Asset Management LLC (0.46%).
View institutional ownership trends.

What other stocks do shareholders of Turnstone Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Turnstone Biologics investors own include Cara Therapeutics (CARA), JPMorgan Chase & Co. (JPM), Avino Silver & Gold Mines (ASM), Bank of America (BAC), Intel (INTC) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSBX
• CIK: 1764974
• Web: turnstonebio.com
• Phone: 347-897-5988
• Fax: N/A
• Employees: 82
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Turnstone Biologics: $0.45
• High Price Target: $0.50
• Low Price Target: $0.40
• Potential Upside/Downside: +26.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -171.86%
• Return on Assets: -128.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.33
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: $19.31 million
• Price / Sales: 0.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 23,140,000
• Free Float: 15,713,000
• Market Cap: $8.21 million
• Optionable: Not Optionable
• Beta: 1.36